We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Exelixis Inc (EXEL) Com Stk Usd0.001

Sell:$16.55 Buy:$16.57 Change: $0.39 (2.41%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Change: $0.39 (2.41%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Change: $0.39 (2.41%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.

Contact details

1851 Harbor Bay Pkwy
United States
+1 (650) 8377000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$5.12 billion
Shares in issue:
316.40 million
United States
US dollar

Key personnel

  • Stelios Papadopoulos
    Independent Chairman of the Board, Co-Founder
  • Michael Morrissey
    President, Chief Executive Officer, Director
  • Christopher Senner
    Chief Financial Officer, Executive Vice President
  • Peter Lamb
    Executive Vice President - Scientific Strategy, Chief Scientific Officer
  • Jeffrey Hessekiel
    Executive Vice President, General Counsel
  • Patrick Haley
    Executive Vice President - Commercial

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.